Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 3/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 13/20 | 0.35 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.32 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483107 | 0.90 | TAOK1 (0.38) | PRSS1PRSS2PRSS3F7F2 | |
| Hydrochloric Acid SCHEMBL6476718 | 0.83 | CFD (0.32) | F7F2 | |
| SCHEMBL6483869 | 0.83 | F2 (0.35) | PRSS1PRSS2PRSS3F2TPSAB1 | |
| SCHEMBL6475472 | 0.79 | F2 (0.35) | PRSS1PRSS2PRSS3F2TPSAB1 | |
| SCHEMBL6487727 | 0.77 | F2 (0.36) | PRSS1F2 | |
| SCHEMBL6476147 | 0.75 | F2 (0.36) | PRSS1F7F2 | |
| SCHEMBL6476971 | 0.75 | F10 (0.38) | PRSS1F2 | |
| SCHEMBL6477095 | 0.72 | F2 (0.38) | F7F2 | |
| SCHEMBL7047178 | 0.71 | F2 (0.48) | PRSS1PRSS2PRSS3F7F2 | |
| SCHEMBL8933084 | 0.71 | F2 (0.33) | F7F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552038-B1 | For use as thrombin inhibitors, coagulation inhibitors and agents for therapy of thromboembolic disorders | ELI LILLY AND COMPANY | 2003-04-22 | — | — | US | claimed |
| EP-0816376-B1 | Trombin inhibitors as anticoagulant agents | LILLY CO ELI (US) | 2002-11-06 | — | — | EP | claimed |
| US-6900319-B2 | Thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20020169318-A1 | Novel thrombin inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-11-14 | — | — | US | disclosed |
| EP-0816376-B1 | Trombin inhibitors as anticoagulant agents | LILLY CO ELI (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6444817-B1 | ANTICOAGULANTS | ABBOTT LABORATORIES | 2002-09-03 | — | — | US | disclosed |
| EP-1110968-A1 | Thrombininhibitors as anticoagulant agents | Eli Lilly & Company (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| EP-0873356-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-28 | — | — | EP | disclosed |
| WO-1996025426-A9 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | — | 1997-06-12 | — | — | WO | disclosed |
| WO-1996025426-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169318-A1 | Novel thrombin inhibitors | TFPI, SERPINC1, F11 | PRSS1 53/4885PRSS2 99/4885PRSS3 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.